How Long Does Cardioversion Last for Irregular Heart Rhythm?

Electrical cardioversion restores a normal heart rhythm immediately in roughly 70 to 90 percent of attempts, but the rhythm does not always stay corrected. For many people with atrial fibrillation, the irregular rhythm returns within weeks to months, and about half of all recurrences happen in the first month. How long the fix lasts depends on factors like how long the arrhythmia has been present, the size of the heart’s upper chambers, whether you take rhythm-stabilizing medication afterward, and how well conditions like sleep apnea or obesity are managed. The procedure itself is quick and generally safe, but the real question for most people is not whether cardioversion works in the moment but whether the result sticks.

How Often Does Cardioversion Work on the First Try

Studies consistently show that electrical cardioversion immediately restores sinus rhythm in a large majority of patients, though exact success rates vary depending on how the procedure is performed and who is being treated. A managed-care study of 370 patients found that about two-thirds had a successful first attempt.¹ A British hospital audit reported a higher rate, with normal rhythm restored immediately in 73 percent of 110 patients.² More recent work using a stepwise protocol, where energy levels are escalated and electrode positions adjusted, pushed acute success above 99 percent across 414 patients.³

A meta-analysis pooling data from several trials placed the overall electrical cardioversion success rate around 89 percent.⁴ The spread from roughly 66 to 99 percent across studies reflects differences in patient selection, how long the arrhythmia had been going on, and how aggressively the clinical team escalated energy and pad placement. In general, if your doctor is using modern biphasic defibrillators with optimized positioning, the odds of restoring a normal rhythm on the day of the procedure are high.

How Quickly the Irregular Rhythm Tends to Come Back

The frustrating reality of cardioversion is that getting back into rhythm is the easy part. Staying there is harder. In one study following 61 patients after successful cardioversion, more than half had a relapse within a single month, with the peak recurrence during the first five days.⁵ That early window is when the heart’s electrical system is most vulnerable to slipping back into its old pattern. The atria essentially have a “memory” of fibrillation, and the longer the irregular rhythm has been present before cardioversion, the more entrenched that memory becomes.

A study of high-risk patients found a total recurrence rate of about 49 percent, with a median time to the first recurrence of five weeks.⁶ Another study looking at patients on rhythm-stabilizing drugs after cardioversion reported that about 70 percent remained free of recurrence at one year, though roughly half of all recurrences happened in the first month.⁷ Without any rhythm-stabilizing medication, the numbers are bleaker: pooled data from randomized trials show one-year recurrence rates of 71 to 84 percent in patients not taking antiarrhythmic drugs.⁸

So the honest answer to “how long does cardioversion last” spans a wide range. Some people stay in normal rhythm for years. Others are back in fibrillation within days. On average, if you do nothing else after the procedure, the odds favor recurrence within a year. With medication and management of underlying conditions, the odds shift meaningfully in your favor, though they never reach certainty.

What Determines Whether the Rhythm Holds

Several factors influence how long you stay in sinus rhythm after cardioversion. The strongest predictor is the size of your left atrium. A meta-analysis found that for every small incremental increase in left atrial volume, the risk of recurrence after cardioversion rises by about 6 percent.⁹ A separate study confirmed that the indexed volume of the left atrium before cardioversion is an independent predictor of recurrence, outperforming the simpler measurement of atrial diameter alone.¹⁰

Why does atrial size matter so much? When the heart has been fibrillating for a long time, the electrical and structural remodeling of the atria becomes self-reinforcing. The atria stretch, scar tissue forms, and the electrical pathways become more disorganized. This is the logic behind the old clinical saying that “atrial fibrillation begets atrial fibrillation.” The longer and more severe the arrhythmia, the harder it is to break the cycle permanently.

A recent analysis of risk factors for failed cardioversion in patients with persistent or long-standing persistent atrial fibrillation identified three that stood out on deeper analysis: duration of the arrhythmia (particularly beyond about four years), a history of heart failure, and an enlarged left atrial volume.¹¹ Not being on antiarrhythmic drugs was also a risk factor in the initial analysis. Female sex, coronary artery disease, and increased cardiac size were associated too, though they dropped out of significance when the other factors were accounted for.

How Medications Improve the Odds

Antiarrhythmic drugs are the primary tool for keeping you in sinus rhythm after cardioversion. A systematic review of randomized trials found that treatment with these drugs reduced one-year recurrence rates from the 71-to-84-percent range down to 44 to 67 percent, depending on which drug was used.⁸ Amiodarone had the lowest number needed to treat (about three patients need to take the drug for one to benefit), while sotalol and quinidine required treating more patients for the same benefit. However, all of these drugs carry side effects, and all but two of the drugs studied increased the risk of proarrhythmia, which is the ironic situation where the rhythm drug itself triggers a dangerous rhythm.

A Dutch study found that flecainide, propafenone, amiodarone, and dronedarone performed similarly in maintaining sinus rhythm after cardioversion, with roughly 70 to 80 percent of patients free of recurrence at one year across all four groups.⁷ The researchers noted that amiodarone, despite being the most commonly prescribed drug in the study, did not outperform the alternatives. Since amiodarone carries well-known risks to the thyroid, lungs, and liver with long-term use, the study raised the reasonable question of whether it should remain the default choice.

Beyond traditional antiarrhythmics, some non-antiarrhythmic medications may offer modest additional protection. In the same high-risk patient study mentioned earlier, mineralocorticoid receptor antagonists (a type of blood pressure drug) were associated with a significant reduction in recurrence, cutting the odds by about 65 percent compared with non-use.⁶ ACE inhibitors, statins, and diuretics showed smaller and non-significant reductions. The evidence here is still developing, and these drugs are not prescribed specifically for rhythm maintenance, but if you are already taking them for blood pressure or heart failure, they may be pulling double duty.

Sleep Apnea, Obesity, and Other Conditions That Undermine Cardioversion

Untreated obstructive sleep apnea is one of the most powerful saboteurs of cardioversion results. A landmark study found that patients with untreated sleep apnea had an 82 percent recurrence rate of atrial fibrillation at 12 months, compared with 53 percent in patients without sleep apnea. Patients whose sleep apnea was treated with CPAP fared much better, with only a 42 percent recurrence rate.¹² A meta-analysis confirmed this pattern, finding that CPAP use was associated with a roughly 40 percent reduction in the risk of atrial fibrillation recurrence.¹³

One randomized trial, however, painted a more nuanced picture: it found identical 25 percent recurrence rates in patients assigned to CPAP versus no CPAP treatment.¹⁴ The discrepancy likely reflects differences in study design and patient populations, but the weight of evidence still leans toward treating sleep apnea as part of a rhythm-control strategy. If you have been cardioverted and you snore heavily, wake up gasping, or feel unrested despite sleeping long enough, getting evaluated for sleep apnea is one of the most impactful things you can do to protect the result.

Obesity also works against you, though the mechanism is partly mechanical. Higher body weight raises the energy threshold needed for the electrical current to reach the atria effectively, which can reduce immediate success rates. Studies have shown that starting at higher energy levels can offset this disadvantage. Beyond the procedure itself, excess weight promotes the structural changes in the atria that drive recurrence, so weight management has longer-term implications for keeping the rhythm stable.

Psychological stress is another factor that receives less clinical attention than it deserves. Stress influences the autonomic nervous system and inflammatory pathways that are directly implicated in triggering and maintaining atrial fibrillation. While no single study proves that reducing stress prevents recurrence after cardioversion, the biological plausibility is strong enough that some clinical programs now incorporate stress reduction as part of comprehensive atrial fibrillation management.

Cardioversion for Atrial Flutter Versus Atrial Fibrillation

Most of the discussion around cardioversion centers on atrial fibrillation, but the procedure is also used for atrial flutter, a related but distinct arrhythmia. The immediate success rate for cardioversion of atrial flutter is even higher, with one long-term study reporting that 96 percent of patients converted to normal rhythm on the first attempt. Without antiarrhythmic drugs, 42 percent of those patients maintained sinus rhythm over a mean follow-up of three and a half years. With serial cardioversion (repeating the procedure when the arrhythmia returned), 90 percent of patients were kept in normal rhythm for five years.⁵ Left atrial size, once again, was the most important predictor of whether a single shock would do the job long-term. Atrial flutter is generally considered more amenable to a cure through catheter ablation of a specific circuit in the right atrium, which is why many flutter patients are ultimately directed toward that procedure rather than repeated cardioversions.

When Cardioversion Keeps Failing and What Comes Next

Repeated cardioversions are common. A study tracking patients over five years found that those who had more cardioversions also had higher rates of atrial fibrillation-related hospitalizations and ultimately higher rates of catheter ablation.¹⁵ This does not mean that repeat cardioversions caused worse outcomes, but it does suggest a pattern: patients who keep needing the procedure are the ones whose arrhythmia is more entrenched and harder to control.

Catheter ablation, which destroys or isolates the tissue that triggers the arrhythmia, is the main alternative for patients who recur despite cardioversion and medication. A randomized trial in patients aged 65 and older compared ablation plus amiodarone to cardioversion plus amiodarone. The ablation group had a dramatically lower burden of atrial fibrillation at one year: about 17 percent of the time in fibrillation, versus roughly 62 percent for the cardioversion group.¹⁶ An interesting finding from a separate study was that how long sinus rhythm lasted after a prior cardioversion did not predict the outcome of a subsequent catheter ablation, meaning a short-lived cardioversion result should not discourage you or your doctor from pursuing ablation.¹⁷

A meta-analysis of rhythm control versus rate control strategies found that pursuing rhythm control (which includes cardioversion, ablation, and antiarrhythmic drugs) reduced death from cardiovascular causes, stroke, and hospitalization for heart failure compared with simply controlling the heart rate and accepting the arrhythmia.¹⁸ The benefit was driven by more contemporary studies that made greater use of ablation, suggesting that the combination of cardioversion as a bridge and ablation as a more durable solution is where modern treatment is heading.

The Anticoagulation Question

Cardioversion carries a small but real risk of stroke. When the heart snaps back into normal rhythm, any blood clot that formed in the fibrillating atrium can be dislodged and travel to the brain. This is why guidelines require anticoagulation (blood-thinning medication) for at least three weeks before an elective cardioversion and at least four weeks afterward. A large study found that both newer oral anticoagulants and warfarin substantially reduced stroke risk compared with no anticoagulation.¹⁹ Acute cardioversion (done urgently rather than on a scheduled basis) appeared to carry higher stroke risk, but this difference disappeared once anticoagulation status was accounted for, reinforcing that the blood thinner, not the timing, is what protects you.

There is a narrow exception for very recent-onset atrial fibrillation. Research has shown that patients whose arrhythmia started within the past 48 hours and who have a low baseline stroke risk may not develop the clotting conditions that make cardioversion dangerous.²⁰ In these carefully selected patients, cardioversion can sometimes proceed without waiting for weeks of anticoagulation. But the key word is “carefully selected.” Your doctor makes this call based on your individual risk factors, and for most people who have been in fibrillation for more than a couple of days, the standard anticoagulation protocol applies.

What Cardioversion Does and Does Not Do for Quality of Life

People undergoing cardioversion often hope for a noticeable improvement in how they feel day to day. The evidence here is more nuanced than you might expect. One study found that patients who maintained sinus rhythm at three months after cardioversion showed significant improvements across nearly all quality-of-life measures, including energy, physical function, and emotional well-being.²¹ A longer-term study confirmed that at six months, patients still in sinus rhythm were considerably less symptomatic, with half experiencing a meaningful reduction in their symptom score.²² Patients who had worse functional capacity before cardioversion tended to gain the most benefit, which makes intuitive sense: if the arrhythmia was limiting you physically, getting back into rhythm has more room to make a difference.

However, a matched comparison found that cardioverted patients did not show greater symptom improvement than similar patients who were not cardioverted.²³ The likely explanation is that the benefit depends entirely on whether you stay in rhythm. If the arrhythmia returns quickly, the quality-of-life gains vanish with it. Interestingly, even patients who were back in fibrillation by three months reported some emotional improvement, possibly from the reassurance of having actively addressed the problem. The practical message is that cardioversion can make you feel substantially better, but only if the rhythm holds, which brings everything back to the question of what you and your doctor do to maintain it.

Electrical Versus Drug-Based Cardioversion

When most people hear “cardioversion,” they picture the electrical version: paddles on the chest, a brief general anesthetic, and a synchronized shock. But pharmacological cardioversion, using intravenous or oral antiarrhythmic drugs to coax the heart back into rhythm, is also widely practiced, particularly for recent-onset atrial fibrillation.

Head-to-head comparisons of the two approaches show remarkably similar initial success rates. One study found 74 percent for drug-based cardioversion and 73 percent for electrical, essentially a coin toss.²⁴ A more recent meta-analysis pooling multiple trials reported no statistically significant difference between the two.⁴ A systematic review focused on refractory atrial fibrillation found that electrical cardioversion tended to have higher success rates in persistent cases, though the overall pooled comparison still did not reach statistical significance, largely because of wide variation between studies.²⁵

One interesting finding is that a strategy of trying drugs first and then following up with electrical cardioversion if the drugs fail can outperform going straight to the shock. That earlier study found a 96 percent overall success rate with the drugs-first strategy compared with 84 percent for electrical-only, a significant difference.²⁴ The choice between the two often comes down to clinical context. Electrical cardioversion is faster and more predictable, making it preferred in urgent situations or for persistent arrhythmias. Drug cardioversion avoids sedation and can sometimes be done outside the hospital, which matters for convenience and cost. Neither approach appears to produce longer-lasting results than the other, since the same recurrence dynamics apply regardless of how the rhythm was initially restored.

Alcohol and Atrial Fibrillation Recurrence

Alcohol consumption is a known trigger for atrial fibrillation episodes, and emerging research suggests it also makes rhythm-control procedures less durable. A high-density mapping study of patients undergoing catheter ablation found that drinkers had a single-procedure success rate of about 79 percent at 12 months, compared with roughly 96 percent in people who abstained from alcohol.²⁶ While that study focused on ablation rather than cardioversion, the biological mechanisms overlap: alcohol is thought to promote the electrical triggers and autonomic imbalances that restart fibrillation regardless of how the rhythm was restored. For people trying to preserve sinus rhythm after cardioversion, reducing or eliminating alcohol is one of the few lifestyle changes with meaningful evidence behind it.